US Moderna revises 24-year sales forecast downward, and sluggishness resonates for the EU
2024/8/2 2:30 AM GMT+9 (some excerpts)
The biopharmaceutical company Moderna revised its 2024 sales forecast for the novel coronavirus vaccine and respiratory syncytial virus (RSV) vaccine downward to 3 billion to 3.5 billion dollars on the 1st.
We anticipate a decline of up to 25%, or 1 billion dollars, from the previous forecast of approximately 4 billion dollars. The reason was that sales to the European Union (EU) were predicted to be extremely low.
The second-quarter financial results were 1.3 billion dollars, or a deficit of 3.33 dollars per share. According to LSEG data, analysts expected a deficit of 3.39 dollars per share.
Total sales for the second quarter were 241 million dollars. The same period last year was 344 million dollars. Sales of the novel coronavirus vaccine “Spikebucks” were 184 million dollars, down 37% from the same period last year, but it greatly exceeded the analysts' average forecast of 66420,000 dollars.
We anticipate a decline of up to 25%, or 1 billion dollars, from the previous forecast of approximately 4 billion dollars. The reason was that sales to the European Union (EU) were predicted to be extremely low.
The second-quarter financial results were 1.3 billion dollars, or a deficit of 3.33 dollars per share. According to LSEG data, analysts expected a deficit of 3.39 dollars per share.
Total sales for the second quarter were 241 million dollars. The same period last year was 344 million dollars. Sales of the novel coronavirus vaccine “Spikebucks” were 184 million dollars, down 37% from the same period last year, but it greatly exceeded the analysts' average forecast of 66420,000 dollars.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
